Dicot Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	67.34	82.44	59.06	45.03	31.67	27.13
Other Operating Expenses	0.49	0.19	0.21	-0	0.13	0.11
Operating Expenses	67.82	82.62	59.28	45.03	31.8	27.25
Operating Income	-67.82	-82.62	-59.28	-45.03	-31.8	-27.25
Interest Expense	-0.01	-0.01	-0.01	-0.07	-0.03	-0
Interest & Investment Income	1.43	2.23	1.57	0.91	-	0
Currency Exchange Gain (Loss)	0.16	0.16	0.03	0.03	0.08	0.05
Other Non Operating Income (Expenses)	0	0	-	-	-	-
EBT Excluding Unusual Items	-66.24	-80.24	-57.7	-44.16	-31.76	-27.2
Gain (Loss) on Sale of Assets	-	-	-	-	-	0.03
Pretax Income	-66.24	-80.24	-57.7	-44.16	-31.76	-27.17
Net Income	-66.24	-80.24	-57.7	-44.16	-31.76	-27.17
Net Income to Common	-66.24	-80.24	-57.7	-44.16	-31.76	-27.17
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	2,062	1,947	1,091	530	120	64
Shares Outstanding (Diluted)	2,062	1,955	1,091	530	121	64
Shares Change	27.00%	79.20%	105.97%	336.53%	89.21%	124.32%
EPS (Basic)	-0.03	-0.04	-0.05	-0.08	-0.26	-0.42
EPS (Diluted)	-0.03	-0.04	-0.05	-0.08	-0.26	-0.42
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-72.15	-85.85	-58.87	-45.23	-29.71	-25.87
Free Cash Flow Per Share	-0.04	-0.04	-0.05	-0.09	-0.24	-0.40
EBITDA	-	-82.62	-59.27	-45.03	-31.79	-27.24
D&A For EBITDA	-	0.01	0.01	0.01	0.01	0.01
EBIT	-67.82	-82.62	-59.28	-45.03	-31.8	-27.25
Revenue as Reported	0.16	0.16	0.03	0.23	0.12	0.08